• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    3 Stocks Under $2 Insiders Are Aggressively Buying

    4/27/22 7:44:12 AM ET
    $PSTV
    $SREV
    Medical/Dental Instruments
    Health Care
    Retail: Computer Software & Peripheral Equipment
    Technology
    Get the next $PSTV alert in real time by email

    US stock futures traded higher this morning ahead of the release of earnings reports from several companies. Investors, meanwhile, focused on some notable insider trades.

    When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

    Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

    Plus Therapeutics

    • The Trade: Plus Therapeutics, Inc. (NASDAQ:PSTV) CEO Marc Hedrick acquired a total of 5,000 shares at an average price of $0.69. To acquire these shares, it cost $3.45 thousand.
    • What’s Happening: Plus Therapeutics recently posted a Q1 loss of $0.19 per share.
    • What Plus Therapeutics Does: Plus Therapeutics Inc is a clinical-stage pharmaceutical company. The company focused on the discovery, development, and delivery of complex and innovative treatments for patients battling cancer and rare diseases.

    ServiceSource International

    • The Trade: ServiceSource International, Inc (NASDAQ:SREV) 10% owner Jonathan Brolin acquired a total of 111,118 shares at an average price of $0.73. The insider spent around $81.26 thousand to buy those shares.
    • What’s Happening: The company is scheduled to release Q1 results on May 10, 2022.
    • What ServiceSource International Does: ServiceSource International Inc is a provider of customer and revenue lifecycle management solutions.

    Also check this: Executives Buy Around $413M Of 3 Stocks

    Don’t forget to check out our premarket coverage here .

    Sharps Technology

    • The Trade: Sharps Technology, Inc. (NASDAQ:STSS) CIO and COO Alan R Blackman acquired a total of 5,000 shares at an average price of $1.37. To acquire these shares, it cost around $6.85 thousand.
    • What’s Happening: Sharps Technology recently priced its IPO at $4.25 per share.
    • What Sharps Technology Does: Sharps Technology Inc is a medical device company. It offers syringes and other safety products.
    Get the next $PSTV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PSTV
    $SREV

    CompanyDatePrice TargetRatingAnalyst
    PLUS THERAPEUTICS Inc.
    $PSTV
    2/3/2026$2.00Buy
    Lake Street
    PLUS THERAPEUTICS Inc.
    $PSTV
    9/3/2025$5.00Hold → Buy
    D. Boral Capital
    PLUS THERAPEUTICS Inc.
    $PSTV
    3/17/2025$9.00Buy
    D. Boral Capital
    More analyst ratings

    $PSTV
    $SREV
    SEC Filings

    View All

    SEC Form 8-K filed by PLUS THERAPEUTICS Inc.

    8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

    1/22/26 7:30:35 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by PLUS THERAPEUTICS Inc.

    8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

    1/16/26 4:05:24 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form 424B4 filed by PLUS THERAPEUTICS Inc.

    424B4 - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

    1/14/26 4:02:19 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    $SREV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Hedrick Marc H converted options into 159,681 shares, increasing direct ownership by 89% to 339,787 units (SEC Form 4)

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    1/2/26 4:30:06 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Sims Andrew John Hugh Macintyre converted options into 38,323 shares, increasing direct ownership by 56% to 106,461 units (SEC Form 4)

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    1/2/26 4:30:04 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Sims Andrew John Hugh Macintyre bought $10,200 worth of shares (20,000 units at $0.51), increasing direct ownership by 42% to 68,138 units (SEC Form 4)

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    11/5/25 8:30:03 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    $SREV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization

    HOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today provides a business update and highlights REYOBIQ clinical progress and CNSide US commercialization. "Our 2 key goals in 2026 are CNSide commercial scale-up and REYOBIQ pivotal trial readiness," said Dr. Marc H. Hedrick, President & Chief Executive of Plus Therapeutics. "Our recently completed upsized $15 million offering will fuel faster progress in these core areas of the business and extend our cash runway through 2027." Overview of anticipated

    1/22/26 7:45:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET

    HOUSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that the Company will provide a business update on Thursday, January 22, 2026 before the market open. Plus Therapeutics' management team will then host a conference call and webcast at 9:00 a.m. ET to discuss and provide additional details. Webcast and Conference Call Date/Time:Thursday, January 22, 2026 @ 9:00 AM ETWebcast:https://event.choruscall.com/mediaframe/webcast.html?webcastid=x5QZCyIkParticipant Dial-in:1-888-349-0106   Please di

    1/21/26 4:15:00 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering

    HOUSTON, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces the pricing of its underwritten public offering of 39,473,684 units, with each unit consisting of one share of common stock and one warrant (the "Warrants"). Each unit is being sold to the public at a price of $0.38 per unit. The gross proceeds to the Company from this offering are expected to be approximately $15 million, before deducting underwriting discounts and commissions and other estimated offering expenses. Each Warrant will be im

    1/14/26 8:00:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    $SREV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Plus Therapeutics with a new price target

    Lake Street initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $2.00

    2/3/26 8:52:26 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics upgraded by D. Boral Capital with a new price target

    D. Boral Capital upgraded Plus Therapeutics from Hold to Buy and set a new price target of $5.00

    9/3/25 8:18:22 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    D. Boral Capital initiated coverage on Plus Therapeutics with a new price target

    D. Boral Capital initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $9.00

    3/17/25 7:41:57 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    $SREV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Sims Andrew John Hugh Macintyre bought $10,200 worth of shares (20,000 units at $0.51), increasing direct ownership by 42% to 68,138 units (SEC Form 4)

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    11/5/25 8:30:03 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Director Lenk Robert P bought $53,779 worth of shares (110,000 units at $0.49), increasing direct ownership by 375% to 139,327 units (SEC Form 4)

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    8/25/25 7:30:05 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Director Hawkins Richard J bought $5,996 worth of shares (4,000 units at $1.50), increasing direct ownership by 36% to 15,188 units (SEC Form 4)

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    9/17/24 7:00:04 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    $SREV
    Leadership Updates

    Live Leadership Updates

    View All

    Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch

    Expands commercial readiness and diagnostic, manufacturing footprint Appoints new leadership in commercial strategy and technical operations HOUSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces continued operational execution and commercial progress in the launch of its wholly owned subsidiary, CNSide Diagnostic LLC's, Cerebrospinal Fluid (CSF) Tumor Cell Enumeration laboratory developed test (LDT). Recent accomplishments include expansion of the CNSide manufacturing footprint,

    10/21/25 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Rishi Bajaj, Founder and CIO of Altai Capital Management and CEO of ContextLogic Inc., Joins Digimarc's Board of Directors

    Bajaj brings broad financial and strategic experience to Digimarc Board as the company builds the trust layer for the modern world. Digimarc Corporation (NASDAQ:DMRC), a pioneer in digital watermarking technologies, today announced the appointment of Rishi Bajaj, founder and CIO of private investment firm Altai Capital Management, L.P. ("Altai") and CEO of ContextLogic Inc., to its Board of Directors. Bajaj's qualifications to serve on the board include extensive investment management, operational, and board experience, particularly in the technology sector. Alongside Bajaj's appointment, Digimarc has entered into a cooperation agreement with Bajaj and Altai Capital Management, L.P.. Th

    7/29/25 8:00:00 AM ET
    $DMRC
    $LOGC
    $MOBL
    EDP Services
    Technology
    Catalog/Specialty Distribution
    Consumer Discretionary

    Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

    HOUSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the appointment of Kyle Guse, J.D., M.B.A. to the Company's Board of Directors where he will serve as chair of the Audit Committee and on the Compensation Committee. "Kyle's decades of financial, transactional and operational experience in our industry will make an immediate and positive impact to Plus' board of directors," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "Furthermore, in his

    4/23/25 8:00:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    $SREV
    Financials

    Live finance-specific insights

    View All

    Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization

    HOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today provides a business update and highlights REYOBIQ clinical progress and CNSide US commercialization. "Our 2 key goals in 2026 are CNSide commercial scale-up and REYOBIQ pivotal trial readiness," said Dr. Marc H. Hedrick, President & Chief Executive of Plus Therapeutics. "Our recently completed upsized $15 million offering will fuel faster progress in these core areas of the business and extend our cash runway through 2027." Overview of anticipated

    1/22/26 7:45:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET

    HOUSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that the Company will provide a business update on Thursday, January 22, 2026 before the market open. Plus Therapeutics' management team will then host a conference call and webcast at 9:00 a.m. ET to discuss and provide additional details. Webcast and Conference Call Date/Time:Thursday, January 22, 2026 @ 9:00 AM ETWebcast:https://event.choruscall.com/mediaframe/webcast.html?webcastid=x5QZCyIkParticipant Dial-in:1-888-349-0106   Please di

    1/21/26 4:15:00 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights

    US market introduction of the CNSide® CSF diagnostics platform, with first national coverage agreement with UnitedHealthcare Presented positive RESPECT-LM Ph1 clinical trial results HOUSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the third quarter ended September 30, 2025 and provides an overview of recent and upcoming business highlights. "Our team continues to execute solidly across the three most important business verticals: diagnost

    10/30/25 4:15:00 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    $SREV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by PLUS THERAPEUTICS Inc.

    SC 13G - PLUS THERAPEUTICS, INC. (0001095981) (Subject)

    6/5/24 7:26:01 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by PLUS THERAPEUTICS Inc. (Amendment)

    SC 13G/A - PLUS THERAPEUTICS, INC. (0001095981) (Subject)

    2/13/23 3:25:03 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by ServiceSource International Inc. (Amendment)

    SC 13D/A - SERVICESOURCE INTERNATIONAL, INC. (0001310114) (Subject)

    5/10/22 4:47:33 PM ET
    $SREV
    Retail: Computer Software & Peripheral Equipment
    Technology